Furaquintinib is mainly used in the treatment of metastatic colorectal cancer, which can effectively prolong the survival of patients and has good clinical efficacy.
Furaquintinib is a tumor angiogenesis inhibitor and is indicated as a single agent for patients with metastatic colorectal cancer who have received prior oxaliplatin, fluorouracil-based and irinotecan-based chemotherapy. Clinical trials have shown that this product is clinically effective in prolonging patient survival by an average of approximately 2 months compared to placebo.
Common adverse reactions of this product include hypertension, proteinuria, vocal difficulties, bleeding, hand and foot skin reactions, transaminase elevation, etc. It is contraindicated for those who are allergic to this product, active peptic ulcers, and those with severe hepatic or renal insufficiency.
Please take the medicine according to the doctor’s instruction under the supervision of the physician.